top of page


Press releases


Sachi Bio receives NIH SBIR award
Sachi Bio wins NIH SBIR award to advance microbiome leads to treat auto-immune diseases. Difficult-to-treat autoimmune diseases that are...
Sep 20, 2022


Sachi Bio selected to join Endless Frontier Labs (EFL) 2022-23 cohort
Sachi Bio has been selected to join the Endless Frontier Labs 2022-2023 cohort alongside 25 ground-breaking companies in the Life...
Sep 15, 2022


Sachi Bio selected in the NASA I-Corps Program
Sachi Bio has been selected in the 2022 cohort of the NASA I-Corps program. The NASA I-Corps program enables small businesses, including...
Aug 2, 2022


Sachi Bio wins NASA Phase I SBIR award to advance drug-discovery on the ISS
May 26, 2022 Rapid, Low-Cost Drug-Discovery in Space In space exploration missions or space tourism outside the earth’s protective...
May 26, 2022


Sachi founders highlighted in “The Shift” column in the Timmerman Report
Out of the University, and in to Outer Space May 23rd, 2022 The Shift, by Lisa Suennen Lisa Suennen, is the managing founder of Venture...
May 23, 2022


Sachi Bio publishes on immunotherapy drug-development in Life Sciences in Space Research
Reversing radiation-induced immunosuppression using a new therapeutic modality May 11, 2022 Immune suppression poses significant health...
May 11, 2022


Sachi Bio wins NASA SBIR Phase II award
Reversing Immune Dysregulation During Spaceflight Missions May 1st, 2022 We are pleased to announce that Sachi Bioworks has won Phase II...
May 1, 2022


Sachi Bio wins Phase I NASA SBIR grant
March 25th, 2021 Sachi Bio will be working with NASA to develop novel therapeutics for radiation countermeasures for deployment in space...
Mar 25, 2021


Subscribe to Our Newsletter
bottom of page

